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Abstract
Lipid metabolism in the ventromedial hypothalamus (VMH) has emerged as a crucial pathway in the regulation of feeding
and energy homeostasis. Carnitine palmitoyltransferase (CPT) 1A is the rate-limiting enzyme in mitochondrial fatty acid b-
oxidation and it has been proposed as a crucial mediator of fasting and ghrelin orexigenic signalling. However, the
relationship between changes in CPT1A activity and the intracellular downstream effectors in the VMH that contribute to
appetite modulation is not fully understood. To this end, we examined the effect of long-term expression of a permanently
activated CPT1A isoform by using an adeno-associated viral vector injected into the VMH of rats. Peripherally, this procedure
provoked hyperghrelinemia and hyperphagia, which led to overweight, hyperglycemia and insulin resistance. In the
mediobasal hypothalamus (MBH), long-term CPT1AM expression in the VMH did not modify acyl-CoA or malonyl-CoA levels.
However, it altered the MBH lipidomic profile since ceramides and sphingolipids increased and phospholipids decreased.
Furthermore, we detected increased vesicular c-aminobutyric acid transporter (VGAT) and reduced vesicular glutamate
transporter 2 (VGLUT2) expressions, both transporters involved in this orexigenic signal. Taken together, these observations
indicate that CPT1A contributes to the regulation of feeding by modulating the expression of neurotransmitter transporters
and lipid components that influence the orexigenic pathways in VMH.
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Introduction
Current lifestyles are responsible for the alarming increase in the
prevalence of obesity and the consequent development of insulin
resistance and Type 2 diabetes. An imbalance between energy
intake and expenditure can cause overweight, thus contributing to
obesity and associated metabolic complications. The hypothala-
mus is crucial to the central control of appetite and energy
homeostasis [1,2]. This brain region consists of interconnected
neuronal nuclei that respond to neuroendocrine and metabolic
signals by modulating the production and release of specific
neurotransmitters that control energy balance [3]. Hypothalamic
lipid metabolism participates in this process and is linked to the
molecular mechanisms by which hormones, such as leptin, ghrelin
and insulin, exert their central effect on food intake [4–6].
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Malonyl-CoA, the first intermediate in fatty acid (FA) biosyn-
thesis, has emerged as a crucial player in the hypothalamic control
of feeding [7,8]. On the one hand, decreased food intake and
increased malonyl-CoA are observed after central treatment of
drugs or anorectic hormones such as leptin. Leptin’s anorectic
pathway involves the inhibition of AMP-activated protein kinase
(AMPK), which, in turn, activates acetyl-CoA carboxylase (ACC),
key enzyme for malonyl-CoA synthesis [5]. Treatments with FAS
inhibitors, such as C75 and cerulenin reduce food intake by an
increase of hypothalamic malonyl-CoA level [8–10]. On the other
hand, malonyl-CoA level decreases under fasting condition when
ghrelin level is high. Orexigenic ghrelin pathway involves
activation of AMPK, inhibition of ACC and a reduction of
malonyl-CoA level [11,12]. One clear candidate for malonyl-CoA
action is carnitine palmitoyltransferase (CPT) 1, a key enzyme
regulating mitochondrial long chain fatty acyl-CoA (LCFA-CoA)
b-oxidation [13], since CPT1 activity is physiologically inhibited
by malonyl-CoA. An accumulation of LCFA-CoA in the
hypothalamus was believed to signal reduction in food intake
and hepatic gluconeogenesis in rodents. CPT1 is related to both
metabolites and it has been implicated in the central control of
both food intake and glucose metabolism [14–17]. Two CPT1
isoforms are expressed in the hypothalamus, CPT1A and CPT1C.
The latter is found mainly in the endoplasmic reticulum of
neurons and does not directly participate in mitochondrial FA b-
oxidation (FAO) [18]. However, CPT1C binds malonyl-CoA and
it may serve as a sensor for malonyl-CoA in the hypothalamic
regulation of energy homeostasis [19,20]. Furthermore, we have
recently shown that CPT1C mediates ghrelin central action by
altering ceramide levels [21]. CPT1A also contributes to the
central orexigenic action of ghrelin, since the molecular events
derived from ghrelin binding to its receptor on hypothalamic
neurons result in increased CPT1A activity and FAO [6,22,23]. It
has been proposed that the derived metabolic changes, including
the accumulation of reactive oxygen species (ROS) and the
subsequent up-regulation of the mitochondrial uncoupling protein
2 (UCP2), contribute to the activation of arcuate (Arc) AgRP
neurons [22]. Moreover, transcription factors such as brain-
specific homeobox (Bsx), cAMP response-element binding protein
(CREB), and forkhead box O1 (FoxO1) act as downstream
mediators of CPT1A in the Arc nucleus for orexigenic neuropep-
tide synthesis [24]. These observations suggest a potential role of
hypothalamic CPT1A in the control of feeding, however the exact
mechanistic sequence and mediators involved are not yet revealed.
A growing body of evidence implicates the ventromedial
hypothalamus (VMH) in the central control of food intake and
regulation of energy homeostasis [17,25,26]. VMH neurons are
reported to activate anorexigenic neuronal pathways in the Arc
nucleus by projecting excitatory inputs into POMC neurons [27].
Moreover, some VMH neurons are GABAergic [28]. We have
recently observed that CPT1A activity in the VMH changes
concomitantly with fasting and refeeding states and that it is
reinforced by the increase in appetite provoked by acute
expression of a permanently activated CPT1A isoform [29].
Despite all the evidence, the exact mechanisms for the induction of
feeding downstream of CPT1A in the VMH are unknown.
Here we examined the long-term effect of AAV-vectorized
expression of a malonyl-CoA-insensitive CPT1A isoform [30],
namely CPT1AM, in the VMH. This model allows us to uncouple
malonyl-CoA effect on food intake and to activate permanently
downstream effectors of CPT1A involved in feeding. We
hypothesise that CPT1A modulates the lipidic and gene profile
of the mediobasal hypothalamus (MBH, encompassing both Arc
and the VMH), which may be involved in the central control of
feeding and glucose metabolism. Long-term CPT1AM expression
led to alterations in MBH structural bioactive lipids, i.e.
phospholipids, sphingolipids and ceramides. In addition, this
CPT1AM expression altered the expression of glutamate and
GABA vesicular transporters, which have been reported to control
amino acid neurotransmitters which alter food intake. Moreover,
hyperphagia, overweight and the later development of insulin
resistance and hyperglycemia was also observed in the CPT1AM
animals. All these results reinforce the notion that VMH CPT1A is
involved in appetite modulation.
Materials and Methods
Adeno-associated vectors (AAVs)
Serotype 1-AAV, AAV-GFP and AAV-CPT1AM were con-
structed to express GFP and CPT1AM respectively. Vector
plasmids carried: CMV promoter, cDNA sequence of GFP or
CPT1AM [30], woodchuck posttranscriptional regulatory element
(WPRE, acc #AY468–486) [31], and bovine growth hormone
polyadenosine transcription termination signal (bases 2326–2533
GenBank acc #M57764). The expression cassette was flanked by
two inverted terminal repeats (ITRs) derived from serotype 2-
AAV. AAVs were produced in insect cells using a baculovirus [32].
The vector preparation used had the following titers: AAV-GFP,
561012 pfu/mL; and AAV-CPT1AM, 2.5?1012 pfu/mL.
Animals
The Comite´ E`tic d’Experimentacio´ Animal de la Universitat de Barcelona
(CEEA-UB) and the Generalitat de Catalunya Department de Medi
Ambient i Habitatge, in accordance with current legislation, approved
all experimental protocols from this work (Permit Numbers: 4068
and 5471). Sprague-Dawley male rats (260–290 g) (Harlan Co.
Laboratories) were used in all the studies. Animals were housed in
individual cages and maintained under a 12 h dark/light cycle
with free access to food (2014, Harlan) and water. Rats were
anaesthetised with intraperitoneal ketamine (Imalgene, 90 mg/kg)
and xylazine (Rompun, 11 mg/kg) and immobilised in a
stereotactic apparatus. Chronic catheters (26-gauge stainless steel
guide cannulae (Plastic one)) were implanted bilaterally in the
VMH (coordinates from Bregma: 22.8 mm posterior, 60.7 mm
lateral and 210 mm ventral [33]). During the week after the
surgery, animals received analgesics (buprenorphine, 0.3 mg/
400 mL) and antibiotics (enrofloxacin, 10%) with water to aid
recovery. Next, rats with VMH cannulae were given bilateral
injections (1 mL/each site) of AAV-GFP (control) or AAV-
CPT1AM at a rate of 0.2 mL/min. Food intake and body weight
were measured in rats infected with AAV-CPT1AM (hereafter
CPT1AM animals) and AAV-GFP (hereafter GFP animals) in the
VMH.
Glucose Tolerance Test (GTT)
The GTT was performed in conscious rats 14 weeks after the
AAV injection in the VMH. Glucose (2.0 g per kg body weight)
was administered intraperitoneally after an overnight fast (16 h),
and blood glucose concentrations were measured using a
Glucometer Elite (Bayer) at baseline and 15, 30, 60, 90 and
120 min after glucose administration.
Measurement of circulating hormones and metabolites
Blood was collected from rats and processed to provide plasma
and serum. Commercial kits were used to measure serum insulin
(Rat/Mouse Insulin ELISA (Millipore)), leptin (Mouse/Rat Leptin
ELISA (B-Bridge)), adiponectin (Rat Adiponectin ELISA (Milli-
pore)), non-esterified FA (NEFA) (Wako Chemicals), plasma
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acylated-ghrelin (Rat Acylated-Ghrelin ELISA (BioVendor)), T3,
T4, and TSH (ELISA (DRG Diagnostics)). For the measurement
of plasma amino acids, distilled water (100 mL), 1000 mM NLE
(50 mL) and (trifluoracetic acid) 10%TFA acid (100 mL) were
added to 100 mL plasma sample. After a 10-min incubation, tubes
were centrifuged at 100006g. The supernatant was filtered
(Ultracel membrane 10 KDa filter (Millipore)), dried under a N2
stream, and redissolved in lithium citrate pH 2.2 (400 mL). Amino
acids were measured at the Scientific-Technical Services of the
University of Barcelona using an auto-analyser (Biochrom 30).
Determination of liver triacylglyceride (TAG) content
Pulverised frozen tissue from rats (<100 mg) was homogenised
in 500 mL PBS. Lipids were extracted using chloroform, dried
under a N2 stream, and redissolved in n-propanol. TAGs were
quantified using the Triglycerides Determination Kit (Sigma
Aldrich).
Determination of malonyl-CoA, LCFA-CoA and
acylcarnitine content
MBH wedges (encompassing Arc and VMH nuclei) and
liver were quickly removed, frozen in liquid nitrogen, and stored
at 280 uC prior to malonyl-CoA or LCFA-CoA quantification.
The former was measured using a malonyl-CoA recycling assay as
described elsewhere [8,34]. LCFA-CoAs were extracted and
measured by HPLC-MS/MS at the Scientific-Technical Services
of the University of Barcelona, as previously described [35].
Acylcarnitines were analysed using an Acquity UPLC-TOF system
(Waters) with an BEH C8 column (1.7 mm particle size,
100 mm62.1 mm, Waters). The two mobile phases were 1 mM
ammonium formate in methanol (phase A) and 2 mM ammonium
formate in H2O (phase B), both phases with 0.05 mM formic acid.
The following gradient was programmed: 0 min, 65% A; 10 min,
90% A; 15 min, 99% A; 17 min, 99% A; 20 min, 65% A, and a
flow rate of 0.3 mL min-1. Quantification was carried out using
the extracted ion chromatogram of each compound, using 50-
mDa windows. The linear dynamic range was determined by
injecting standard mixtures. Positive identification of compounds
was based on the accurate mass measurement with an error ,
5 ppm and their LC retention time compared to that of a standard
(62%).
Lipidomic analysis
MBH wedges were quickly removed, frozen in liquid nitrogen,
and stored at 280 uC prior to lipid analysis. Sphingolipid
extraction and analysis by UPLC-TOF was carried out as
described [36]. Phospholipid extracts were obtained using the
same procedure but without the saponification step. Lipids were
analysed by UPLC-TOF in positive or negative mode. The two
mobile phases were 1 mM ammonium formate in methanol (phase
A) and 2 mM ammonium formate in H2O (phase B), both phases
with 0.05 mM formic acid. The following gradient was pro-
grammed: 0 min, 80% A; 3 min, 90% A; 6 min, 90% A; 15 min,
99% A; 18 min, 99% A; 20 min, 80% A, and a flow rate of
0.3 mL min21.
Histological analysis
Brain histological examination was done using 50- mm thick
sections. Brains were excised and fixed overnight in 10% neutral-
buffered formalin (Sigma). Next, they were immersed in 20%
sucrose phosphate-buffered solution (PBS; pH 7.0) for 18–
36 h at 4 uC. Coronal sections were obtained using a freezing-
sliding microtome and mounted onto microscope slides using
Immu-Mount (Thermo) to prevent fading. Examination of white
adipose tissue (WAT), brown adipose tissue (BAT), and liver
histology were done using 4- mm thick formalin-fixed, paraffin-
embedded tissue sections stained with hematoxylin and eosin
(H&E) at the Pathology Department of Hospital Clı´nic of Barcelona.
mRNA expression analysis
The MBH, liver, WAT, and BAT from GFP and CPT1AM rats
were excised, frozen, and stored at -80 uC. Total RNA was isolated
from frozen MBH, WAT, and BAT using RNeasy Lipid Tissue
Mini-Kit (Qiagen) and from frozen liver using RNeasy Mini-Kit
(Qiagen). cDNA was synthesised using the Transcriptor First
Strand cDNA Synthesis Kit (Roche). qRT-PCR analyses were
performed in a LightCycler 480 Instrument (Roche). To discern
between the endogenous CPT1A (CPT1Awt) and the expressed
isoform CPT1AM, we used specific primers and FRET probes
and a LightCycler 480 Probes Master (Roche). The mRNA
expression of other genes was determined using intron-skipping
primers and SYBR Green Master Mix (Applied Biosystems). All
sequences are available upon request.
Statistical analysis
Data are expressed as mean 6 SEM. Statistical significance was
determined by ANOVA and Student’s t test, using Microsoft Excel
and GraphPad Prism 6 software. A p value , 0.05 was considered
significant.
Results
AAV-mediated expression of GFP and CPT1AM
AAV carrying CPT1AM or GFP were obtained for long-term
expression of the permanently active form of CPT1AM or GFP
(Fig. 1A). AAV vectors were bilaterally injected into the VMH and
several experiments were performed according to the showed
scheme (Fig. 1B). Histological studies in GFP rats revealed that
AAV-infected cells in the hypothalamus were limited mainly to the
VMH (Fig. 1C). qRT-PCR analyses performed in MBH showed a
robust 113619.2-fold increase (p,0.0001) in the CPT1AM
mRNA in CPT1AM rats with respect to GFP control rats
(Fig. 1D). We analysed the levels of the long-chain acylcarnitines,
as direct products of CPT1A activity in MBH samples. The levels
of C18:0-acylcarnitine increased 3.3-fold in CPT1AM
(298.4672.62 pmol/mg) compared to GFP-expressing counter-
parts (90.46612.69 pmol/mg, p,0.05). C14:0- and C16:0-acyl-
carnitine levels also increased, but not significantly (Fig. 1E).
CPT1AM expression in the VMH increased food intake
and led to obesity, hyperglycemia and insulin resistance
We monitored the food intake and body weight of CPT1AM
and GFP rats fed regular chow. The former group showed
hyperphagia compared to GFP animals. Cumulative food intake
was significantly higher 20 days after AAV injection (912630.7 vs.
798617.8 g, p,0.05) This increased food intake was maintained
until the sacrifice (Fig. 1F). Furthermore a fast-refeeding test was
performed to discern if this increased food intake may be due to
impaired satiety. CPT1AM rats showed increased food intake in
all measures performed after refeeding (Fig. 1G). Body weight was
also measured. CPT1AM rats showed a significantly higher
(83.8613.7 g vs. 57630.7 g, p,0.05) body weight change 20 days
after AAV injection (Fig. 1H).
Glucose tolerance, blood glucose and serum insulin concentra-
tions were examined in fasted CPT1AM and GFP rats. Fourteen
weeks after the AAV injection, the GTT demonstrated glucose
intolerance in the former (Fig. 1I). When sacrificed, CPT1AM rats
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showed higher fasting glucose (increase of 16.463.3%, p,0.01)
and insulin (increase of 31.669.2%, p,0.01) than GFP animals
(Fig. 1J and 1K). Furthermore, the expression of key gluconeo-
genic enzymes, such as glucose-6-phosphatase (G-6-Pase) and
phosphoenolpyruvate carboxykinase (PEPCK), was analysed in
the liver of fasted GFP and CPT1AM animals (Fig. 1L). Results
showed a 260.3-fold and 1.660.5-fold increase in G-6-Pase and
PEPCK mRNA respectively in CPT1AM animals with respect to
controls (p,0.05). These results correlate with the hyperglycemia
observed in the CPT1AM rats (Fig. 1J). The analysis of liver
mRNA levels of lipid metabolism-related genes revealed a
2.160.3-fold increase in acetyl-CoA carboxylase 1 (ACC1) in
CPT1AM rats (p,0.01) (Fig. 1L). However, we found no
significant changes in the hepatic concentration of TAG
(Fig. 1N). In addition, histological liver examination revealed no
major differences in the hepatic anatomy of between the two
groups (Fig. 1M).
Next we studied the circulating metabolic and hormonal
profile of GFP and CPT1AM rats. In parallel with the increase in
food intake, fed CPT1AM animals presented a significant rise
(3.361.4-fold increase, p,0.001) in post-absorptive plasma levels
of ghrelin (octanoylated/active form) (Fig. 2A). In addition, they
exhibited high serum NEFA levels (260.3-fold increase, p,0.05)
(Fig. 2B) equivalent to those of fasted GFP and CPT1AM
counterparts (data not shown). Levels of other hormones
associated with energy metabolism, such as thyroid hormones
(T3, T4 and TSH, data not shown), leptin and adiponectin, were
unaltered between the two groups (Fig. 2C, 2D). In addition, we
found significant differences in the plasma aminogram of the two
groups of animals (Table 1). Interestingly, specific branched-
chain amino acid (BCAA), such as Val and Ile, considered
markers of obesity, increased by 18.8% and 19.8% respectively in
CPT1AM animals (Table 1). Obesity is characterised by
hyperplasia in WAT and britening of BAT. Histological
examination of epididymal WAT revealed that white adipocytes
from CPT1AM animals were significantly larger than those of the
GFP controls (Fig. 2E and F). Analyses of the mRNA expression
of pro-inflammatory cytokines showed an up-regulation of the
monocyte chemoattractant protein-1 (MCP1) (1.660.4-fold
increase, p,0.05) in CPT1AM WAT with respect to GFP
WAT (Fig. 2G). BAT showed a brown-to-white transformation in
CPT1AM rats (Fig. 2H and I). We also determined the mRNA
expression of genes associated with thermogenesis and FA
metabolism in BAT. A moderate increase (1.260.1-fold, p,
0.01) in the expression of CPT1B in CPT1AM rats was detected
with respect to GFP controls (Fig. 2J). All these results indicate
that the expression of CPT1AM in the VMH impairs satiety and
leads to an obesogenic phenotype.
CPT1AM expression in the VMH alters MBH mRNA levels
of different genes involved in food intake
To discern the molecular mechanisms involved in the hyper-
phagia produced by CPT1AM expression in the VMH, we first
analysed markers of excitatory inputs from the VMH to POMC
neurons in Arc in fasted MBH of AAV-infected rats. We observed
an 82% decrease (p,0.05) in VGLUT2 mRNA levels in
CPT1AM rats, without any change in VGLUT1 or VGLUT3.
This observation correlates with the finding of unaltered POMC
and CART mRNA levels (Fig. 3A) and indicates that the
anorexigenic response was not activated.
Vesicular GABA transporter (VGAT) showed a 2.260.4-fold
increase (p,0.05) in the MBH in CPT1AM rats. However, no
changes were observed in the mRNA levels of other orexigenic
neurotransmitters (such as NPY, AgRP) (Fig. 3A). Interestingly,
the mRNA levels of three key transcription factors involved in the
expression of the aforementioned orexigenic neuropeptides
[21,37,38], namely Bsx, CREB and FoxO1, were up-regulated
in fasted CPT1AM rats (Fig. 3A) (Bsx: 1.860.2-fold increase, p,
0.05; CREB: 1.360.1-fold increase, p,0.01 and FoxO1: 1.560.2-
fold increase, p,0.01). Taking into account that the orexigenic
neuropeptide NPY exerts its effect on food intake mainly by
binding to receptors Y1 (NPY1R) and Y5 (NPY5R), we measured
the mRNA levels of these receptors. The NPY1R mRNA level was
higher in CPT1AM animals than in controls (2.760.5, p,0.05)
(Fig. 3B), and no changes were observed in NPY5R. Since serum
levels of ghrelin were increased in CPT1AM rats, we analysed the
mRNA levels of ghrelin receptor (GHS-R), which is known to be
induced in fasting conditions [39]. A 1.660.2-fold increase in
GHS-R (p,0.05) was detected, while no changes in mRNA levels
of other receptors, such as MC3R, MC4R and ObRb, were
observed (Fig. 3B). All these results show that increased VMH
CPT1A alters different pathways involved in the control of food
intake.
GABAergic transmission is modulated by ROS [40]. Given
that CPT1AM expression putatively increases mitochondrial
FAO and ROS, we measured the mRNA expression of anti-
oxidant enzymes and UCP2 (Fig. 3C). A moderate increase in
the mRNA levels of catalase (CAT), glutathione peroxidase 3
(Gpx3), superoxide dismutase (SOD) (1.260.04, 1.560.1 and
1.260.03-fold increase respectively, p,0.01) and UCP2
(1.460.1-fold increase, p,0.05) was detected in CPT1AM
animals with respect to GFP controls. However, the markers of
ER stress were not induced in VMH CPT1AM rats (Fig. 3C).
These data suggest that increased ROS production in the
VHM of CPT1AM rats may modulate GABAergic vesicular
transporter.
Figure 1. Analysis of the effect of VMH CPT1A expression on feefing behaviour and glucose homeostasis. (A) Scheme of the AAV
vectors used in this study: AAV-GFP and AAV-CPT1AM. The cassettes contain the GFP or CPT1AM transgene driven by the cytomegalovirus (CMV)
promoter. (B) Scheme of the time course of the experiment. (C) Representative histological section showing GFP in the VMH of GFP rats 2 weeks after
the bilateral injection of AAV vector. (D) CPT1Awt and CPT1AM mRNA expression in the MBH (VMH + Arc) of GFP and CPT1AM rats. Measurements
were performed 18 weeks after the bilateral injection of AAV vectors. Primers specifically recognise the sequence of wt or mutant CPT1A. (E)
Acylcarnitines were measured as an indirect parameter of CPT1A activity. n= 3 (F) Cumulative food intake, (G) fast-refeeding test and (H) body weight
change in rats fed a normal diet. n=11. In E and G, X-axis represents days after the bilateral injection of AAV vectors into the VMH. (I) Intraperitoneal
GTT in GFP and CPT1AM animals after an overnight fasting. The test was performed in animals 14 weeks after the AAV-injection into the VMH. (J)
Blood fasting glucose and (K) serum fasting insulin levels measured in GFP and CPT1AM rats 18 weeks after the bilateral injection of AAV vectors into
the VMH. The following analyses were performed 18 weeks after the AAV-injection into the VMH. (L) Liver relative mRNA expression of genes
associated with gluconeogenesis and lipid metabolism in GFP and CPT1AM rats. (M) Liver histological sections (H & E staining) from representative
GFP and CPT1AM rats. (N) Liver TAG content in GFP and CPT1AM animals. n= 5–6 animals in all cases. Error bars represent SEM. *p,0.05. AUC: area
under the curve.
doi:10.1371/journal.pone.0097195.g001
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CPT1AM expression in the VMH alters fatty acid
metabolism and the lipidomic profile in the MBH
Previous reports indicate that LCFA-CoA levels in the
hypothalamus act as a signal in the pathways that modulate food
intake. Interestingly, animals with long-term CPT1AM expression
in the VMH did not show a reduction of total LCFA-CoA in the
MBH (Fig. 4A), in contrast to animals with short-term expression
of this isoform [29]. In fact, the levels of C18:0 LCFA-CoA
increased in the former (Table 2). We then analysed the mRNA
Figure 2. Analysis of postprandial metabolic and hormonal profile, adipose tissue histology, and mRNA expression in GFP and
CPT1AM rats. Serum and plasma samples from fed GFP and CPT1AM rats were used for all the analyses. (A) Plasma active ghrelin. (B) Serum non-
esterified fatty acids (NEFA). (C) Serum leptin. (D) Serum adiponectin. n=6–10 animals per group. (E) Epididymal WAT histological sections (H & E
staining) from representative GFP and CPT1AM rats. (F) White adipocyte diameter scored using ImageJ software and expressed as a fold change
respect to GFP animals (5 high power field counted per rat, n=3 rats per group). (G) mRNA expression of pro-inflammatory markers in WAT from GFP
and CPT1AM rats. n=5–7 animals per group. (H) Interscapular BAT histological sections (H & E staining) from representative GFP and CPT1AM rats. (I)
Lipid droplet size scored using ImageJ software and expressed as a fold change respect to GFP animals (4 high power field counted per rat, n=3 rats
per group). (J) mRNA expression of genes associated with lipid metabolism and thermogenesis in BAT from GFP and CPT1AM animals. n=10 animals
per group. Error bars indicate SEM. *p,0.05.
doi:10.1371/journal.pone.0097195.g002
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levels of key genes involved in de novo FA synthesis (Fig. 4B).
CPT1AM animals showed a 2.160.1-fold increase in FA synthase
(FAS) mRNA (p,0.05). Since hypothalamic malonyl-CoA levels
have been proposed to regulate feeding, we also measured the
concentration of this compound in the MBH of the two
experimental groups. Concentrations of this metabolite showed
no differences between groups (Fig. 4C). This finding is consistent
with the absence of changes in ACC1 and ACC2 between the two
groups in the MBH (Fig. 4B). On the basis of these observations,
we conclude that the hyperphagic phenotype observed in our
model is independent of the variations of these two metabolites.
To find out whether other bioactive lipids are involved in the
orexigenic effect of VMH CPT1AM expression, we performed a
lipidomic study of the MBH. Recent evidence has linked ceramide
concentration in the hypothalamus to appetite modulation
[20,21]. In our model, total ceramide levels were not significantly
different; however, an analysis by species showed an increase in
14:0-ceramide (AAV-GFP, 5.360.7 pmol/mg, AAV-CPT1AM,
8.361.0 pmol/mg, p,0.01) and 18:1-ceramide (AAV-GFP,
170.4618.8 pmol/mg, AAV-CPT1AM, 250.5631.9 pmol/mg,
p,0.02) levels (Fig. 4D, Table 2). We also observed a 36.1%
increase in total lactosylceramides (LacCer) in CPT1AM rats
(Fig. 4D). Furthermore, other sphingolipids related to ceramides,
such as sphingomyelin (SM) and dihydrosphingomyelin (DHSM),
were analysed. Total concentrations of SMs and DHSMs were
increased by 30.8% and 30.6%, respectively in the MBH of
CPT1AM animals.
Membrane traffic and vesicular fusion are especially sensitive to
the amount of phosphatidylethanolamine (PE) [41]. We deter-
mined the total levels of lysophosphatidylethanolamine (LPE),
plasmalogen-phosphatidylethanolamine (PlasPE), and lysoplasma-
logen (LPlasPE) and found them to be decreased by 38.5%,
29.0%, 45.8% respectively in CPT1AM rats with respect to
controls. The concentration of lysophosphatidylserine (LPS) was
also analysed in the MBH, finding it to be decreased by 39% in
CPT1A animals (Fig. 4E). Interestingly, the amount of lysophos-
phatidylcholine (LPC) was 30.0% higher in CPT1AM animals
than in controls, even though no changes were observed in total
phosphatidylcholine (PC) and plasmalogenphophatidylcholine
(PlasPC). Neutral lipids (TAG, DAG and cholesterol esters) were
not significantly different between groups (data not shown). All
these observations indicate that CPT1A expression in the VMH
changes lipid metabolic flows and alters the profile of structural
and bioactive complex lipids in the MBH, which may be involved
in the hyperphagic phenotype observed.
Discussion
The hypothalamus is a critical site in the regulation of food
intake and energy homeostasis. The VMH has been considered a
satiety centre, since lesion of the nucleus induces hyperphagia and
Table 1. Analysis of plasma amino acids from CPT1AM and GFP rats.
GFP-expressing rats CPT1AM-expressing rats
Amino acids (mM) n=6 n= 6 p value
Taur 13269 128610.1 ns
Asp 23.760.8 26.761.2 ns
Hypro 1.660.2 1.760.1 ns
Thr 198.5611.1 216.769.6 ns
Ser 216.266 221.465.6 ns
Asn 30.461.1 30.562.3 ns
Glu 192.4615.8 265.1612.3 ns
Gln 103.169.8 91.3610.1 ns
Pro 70.861.5 67.562.7 ns
Gly 25167.4 223.168.3 0.04
Ala 335611.3 324.3610.7 ns
Citr 66.463.5 71.263.8 ns
Val 159.466.2 18965.8 0.006
Cyst 5061.4 57.163.1 ns
Met 78.562.4 77.164.5 ns
Ile 66.162.5 79.262.2 0.003
Leu 194.366.9 204.963 ns
Tyr 127.568.4 144.768 ns
Phe 7562.8 79.760.9 ns
Orn 115.563.2 16367.1 0.004
Lys 63269.1 696.1625 0.05
His 101.362.7 122.462.8 0.001
Trp 21.961.5 20.862 ns
Arg 215.469.4 225.966.3 ns
Analysis was performed on plasma obtained at 18 weeks after AAV injection. Data indicated as Mean 6 SEM.
doi:10.1371/journal.pone.0097195.t001
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obesity [26,42]. Several years ago, the focus of research into food
intake control shifted from the VMH to the Arc with the
development of cell-specific molecular tools to study its impact
[22,43,44]. Nonetheless, the critical role of the VMH in the
control of food intake and energy homeostasis has attracted
renewed attention. This has arisen as a result of recent studies in
knock-out mice in VMH-specific SF1 cells [26,45], the discovery
of neuronal connections between the various hypothalamic nuclei
[27], and the crucial role of the Arc- and VMH-originated classical
amino acid neutrotransmitters in the control of food intake [46–
50]. FA metabolism is a key component in the regulation of food
intake. We have recently reported that acute expression of
CPT1AM, which is insensitive to malonyl-CoA, produces
hyperphagia [29]. In the present study we have taken advantage
of AAV vectors to demonstrate for the first time that long-term
increased CPT1A expression in the VMH produces a chronic
hyperphagia and body weight gain. Amongst others, this might be
a result of the alteration of vesicular amino acid transporters
expression, which are involved in the glutamatergic and
GABAergic neurotransmission. Moreover, the alteration on the
lipidomic profile found in CPT1AM rats could explain these
effects too. These findings emphasise the key role of VMH CPT1A
expression in the hypothalamic control of appetite and body
weight.
Our data confirm that CPT1AM expression in the VMH
produces hyperphagia, as seen by the unsated state of CPT1AM
rats. Such chronic over-feeding may contribute to the phenotype
observed: CPT1AM rats present overweight and a progression
towards insulin resistance, glucose intolerance and hyperglycemia.
However, this hyperglycemia may be caused by the direct action
of VMH CPT1AM expression. It has been reported that
glutamatergic outputs from the VMH exert their effect on liver
and thus control gluconeogenesis [51]. This observation is
consistent with the observed up-regulation of liver gluconeogenic
genes in CPT1AM rats, which show a decreased expression of the
glutamatergic VGLUT2. In addition, these animals showed
increased adiposity. This centrally driven direct effect may also
be involved in the brown-to-white modification of BAT of VMH
Figure 3. Analysis of MBH gene expression of GFP and CPT1AM rats. All analyses were performed 18 weeks after the AAV-injection into the
VMH. (A) MBH relative mRNA expression of hypothalamic vesicular classical neurotransmitter transporters, hypothalamic neuropeptides, transcription
factors. (B) Receptors for neuropeptides and hormones involved in feeding regulation and genes associated with fatty acid metabolism. (C) UCP2 and
anti-oxidant enzymes and ER stress-related genes. n=6–7 animals per group in all panels. Error bars indicate SEM. *p,0.05.
doi:10.1371/journal.pone.0097195.g003
Figure 4. Lipid profile analysis in the MBH of GFP and CPT1AM rats. (A) Relative LCFA-CoA and (B) malonyl-CoA content in the MBH. (C)
Sphingolipid (SLs) and (D) phospholipid (PLs) levels in the MBH. n= 5-8 animals per group in panels A and B. n= 10 animals per group in panels C, D
and E. Error bars represent SEM. *p,0.05. DAG: diacylglycerol; TAG: triacylglycerol; Cho-E: cholesterol ester; Cer: ceramide; DHCer: dihydroceramide;
SM: sphingomyelin; DHSM: dihydrosphingomyelin; GlucCer: glucosylceramide; GlucDHCer: glucosyldihydroceramide; LacCer: lactosylceramide; PE:
phosphatidylethanolamine; LPE: lysophosphatidylethanolamine; PlasPE: plasminogen phosphatidylethanolamine; PS: phosphatidylserine; LPS:
lysophosphatidylserine; PI: phosphatidylinositol.
doi:10.1371/journal.pone.0097195.g004
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CPT1AM rats. In support of this notion, VMH has been
implicated in the modulation of BAT thermogenesis through
parasympathetic innervation [52,53]. We detected lipid accumu-
lation and hypertrophy in WAT. Although these conditions may
be a direct effect of CPT1AM expression in the VMH, we cannot
discard indirect mechanisms such as the effect of ghrelin on
peripheral tissues [54–56].
In our hands, fed VMH CPT1AM rats showed increased
circulating levels of the appetite-stimulating hormone ghrelin and
NEFA, thus mimicking the metabolic status of fasting animals
during the postprandial phase. The relationship between ghrelin
hypothalamic signalling and CPT1A activity is well established
[22,23,29,56]. Nevertheless, the observation of increased ghrelin
levels as a result of VMH CPT1AM expression is striking, since it
may indicate a connection between the VMH and the stomach,
which is the main producer of octanoylated ghrelin. This notion is
reinforced by the observation of reduced ghrelin levels in response
to icv administration of C75 [57], a compound that inhibits FAS
and CPT1A [35]. Nonetheless, further research is required to
confirm these physiological findings.
The molecular mediators in the orexigenic signalling triggered
by CPT1A in the VMH are not clear. Although little attention has
been given to amino acid neurotransmitters in the control of food
intake, their role in hunger signalling has been recently
highlighted. Glutamatergic outputs from the VMH have been
described to activate anorexigenic POMC/CART neurons to
stimulate satiety signalling [27]. In the MBH of rats expressing
CPT1AM in the VHM, we observed diminished mRNA levels of
VGLUT2, which is the main vesicular glutamate transporter in
that nucleus (Fig. 3). Such a decrease may lead to a reduction in
glutamate quantal size in the VMH, which would in turn attenuate
the activation of anorexigenic neurons. Moreover, optogenetic
stimulation on NPY/AgRP neurons produces an orexigenic effect
that is blocked using GABA antagonists. This finding indicates that
the orexigenic signalling was not dependent on peptidergic
neurotransmission [50]. We observed an increase in VGAT
expression, which may produce a rise in GABAergic signalling.
This inhibitory signalling may come from the VMH [58] and/or
from NPY/AgRP neurons [59] to anorexigenic POMC/CART
neurons. This notion is consistent with the experiments in which
injections of the GABA agonist muscimol markedly increased food
intake [60]. Although we do not know how the vesicular
transporters are modulated in our model, ROS signalling has
been reported to boost GABA release [40]. For this reason, we
hypothesise that CPT1AM expression in the VMH, which
increases ROS, might be responsible for this higher inhibitory
output. Although we did not monitor ROS directly, we observed
an increase in the transcription of ROS-buffering enzymes.
Alternatively, the lipidomic profile modification driven by
CPT1AM expression could be responsible for the increased food
intake. CPT1A alters the lipid profile in neurons [61], and
membrane composition is crucial to maintain the structure and
functionality of embedded proteins [62–65]. In some physiopath-
ological states, neurotransmission is modified by alterations in
membrane lipid composition [66]. In the synaptic vesicular model
developed by Takamori et al., transmembrane proteins encompass
one fourth of the whole vesicular surface [64]. Among them,
vesicular amino acid transporters, such as VGAT and VGLUT2,
require their phospholipidic rims to be anchored to the lipid
bilayer and to have a correct functionality [63,64]. The reduction
in phospholipids observed in our model may affect the function-
ality of these transporters, thus impairing their transcription in
some way, at least in the case of VGLUT2. Notwithstanding, we
hypothesise that the putative increased VGAT mRNA levels
occurs as a result of other factors, such as an indirect effect on
other regions within the MBH, mainly Arc, or the aforementioned
ROS-induced up-regulation. Both changes in lipid composition
and expression of glutamatergic and GABAergic transporters may
be implicated in the increase of food intake in animals with
CPT1AM expression in the VMH (Fig. 5). Accordingly, we did
not observe changes in POMC or CART expression in this animal
model or an increase in NPY or AgRP mRNA levels. This could
Table 2. LCFA-CoA and ceramides levels in MBH from CPT1AM and GFP rats.
GFP-expressing rats CPT1AM-expressing rats
LCFA-CoA (pg/mg protein) n= 5 n= 7 p value
16:0 160.2 1.260.1 ns
18:0 0.1960.04 0.360.02 0.02
18:1 ns
Ceramides (pmol/mg protein) n= 10 n= 10 p value
14:0 5.360.7 8.361 0.01
14:1 2.760.4 460.7 ns
16:0 66.369.6 84.9613.1 ns
16:1 7.361.1 9.561 ns
18:0 1479.96177.9 1880.86165.9 ns
18:1 170.4618.8 250.5631.9 0.02
20:0 246.9641.3 312.4623.9 ns
22:0 40.366.9 5167.1 ns
22:1 10.661.3 12.561.2 ns
24:0 61.269.4 67.1613.5 ns
24:1 6567.8 67.5610.5 ns
24:2 24.363.5 29.163.6 ns
Analysis was performed on MBH extracts obtained at 18 weeks after AAV injection. Data indicated as Mean 6 SEM.
doi:10.1371/journal.pone.0097195.t002
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be attributed to the fact that we measured these transcripts in
fasting conditions, where both CPT1AM and control GFP rats
may express high levels of these orexigenic neuropeptides.
However, the transcription factors BSX, CREB and FoxO1,
involved in NPY and AgRP expression, were induced in CPT1AM
rats [21,37,38].
In addition, our results indicate that long-term expression of
CPT1AM raises sphingolipid levels in the MBH. It has recently
been demonstrated that hypothalamic ceramide metabolism
participates in feeding regulation [20]. In particular, the brain-
specific CPT1C is required for the fasting-induced increase in
hypothalamic ceramides [21]. The present data also implicate
CPT1A in ceramide metabolism, as CPT1AM rats showed a
significant increase in the hypothalamic concentrations of 18:1 and
14:0-ceramides. Sphingolipids act as signalling molecules in a
variety of physiological processes, including neuronal development
and plasticity. The formation and transport of specific axonal
vesicles has been reported to be coupled to sphingolipid synthesis
[67]. Here we observed that CPT1AM expression alters sphingo-
lipid metabolism by increasing SM and DHSM, and it may lead to
the modification of hypothalamic synaptic plasticity and energy
balance. However, further research is required to test this notion
and to clarify the contribution of CPT1A and CPT1C isoforms to
hypothalamic sphingolipid metabolism and feeding modulation. In
addition, CPT1A expression in the VMH reduces phospholipids in
MBH. Although concrete lipid metabolic flows were not the
objective of this study, we hypothesise that phospholipids may
serve as fuel for increased FAO in CPT1AM-expressing neurons.
Previous hypotheses assume that LCFA-CoAs signal nutrient
availability in the hypothalamus and modulate food intake control
[14,15]. Accordingly, in collaboration with Lopaschuck’s group
[29], we observed that short-term expression of CPT1AM in the
VMH produces hyperphagia and reduced LCFA-CoA concentra-
tion in MBH neurons. Nonetheless, here we show that total
Figure 5. Proposed role of VMH CPT1A in the hypothalamic control of satiety. AAV-mediated CPT1AM expression in the VMH would
increase FAO and modulate ROS production and the cellular profile of SLs and PLs. The derived molecular changes in the hypothalamus include the
up-regulation of the mitochondrial protein UCP2, the enzyme FAS, and the receptors NPY1R and GHS-R, which indicate an enhanced response to
orexigenic NPY and ghrelin. Moreover, an up-regulation of VGAT transporter and a decrease in VGLUT2 may indicate enhanced inhibitory signalling
which has been described to promote food intake. The long-term de-regulation of hypothalamic energy sensing induces systemic modifications,
including increased circulating levels of BCAA, NEFA, ghrelin, insulin and glucose, the up-regulation of hepatic gluconeogenic genes, increased
adiposity, and MCP1 expression in WAT. These central and systemic changes derived from VHM CPT1AM expression promote an increase in food
intake and the development of associated metabolic complications.
doi:10.1371/journal.pone.0097195.g005
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hypothalamic LCFA-CoA content in hyperphagic long-term
CPT1AM-expressing animals was similar to GFP control rats
and, specifically, the concentration of 18:0-LCFA-CoA was
significantly higher in the former. This discrepancy with our
previous study might be a consequence of the adaptability of FA
metabolism to long-term CPT1AM expression and poses the
question as to whether hyperphagia is dependent on LCFA-CoAs
levels or whether it relies only on CPT1A activity.
In conclusion, our results indicate that CPT1A expression in the
VMH plays a key role in the regulation of food intake and glucose
homeostasis (Fig. 5). Mechanistically, our findings suggest that
CPT1A modulates mRNA levels of glutamatergic and GABAergic
neurotransmission markers and transcription factors controlling
orexigenic neuropeptides. Since CPT1AM modifies the composi-
tion of sphingolipids and phospholipids and also boosts ROS
formation, we cannot discard a mechanistic involvement of these
species. Taken together, these data shed light on the central
molecular mechanism controlling appetite and highlight mito-
chondrial FAO in the hypothalamus as a potential target for the
treatment of obesity and other eating disorders.
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